PD06 Efficacy of dupilumab in chronic actinic dermatitis

Abstract Chronic actinic dermatitis (CAD) is characterized by a photoexposed site in association with objective evidence of photosensitivity, often arising on background atopic (AD). Dupilumab monoclonal antibody that inhibits signalling interleukin (IL)-4 and IL-13 licensed for the management moderate-to-severe AD. To date, nine case reports have suggested dupilumab can be clinically effective CAD, yet only five cases had diagnostic baseline phototesting two could demonstrate improvement photosensitivity repeat testing. We report retrospective series from UK photobiology units 11 patients concomitant AD CAD treated dupilumab. Inclusion criteria included an irradiation monochromator device confirming diagnosis < 3 years prior to starting dupilumab, repeated after at least 16 weeks all were refractory or intolerant one other systemic therapy Eleven [82% male, median age 40 (range 21–59) diagnosis] skin phototypes I–V included. All pre-existing before onset also allergic contact dermatitis. The average duration was 15 months 4–44). Ten (91%) reported their terms both rash pruritus. Five (45%) partial subjective whom showed ultraviolet B (3- 6-fold). Six (55%) no clinical change worsening phototesting; while four improvements, they remained severely photosensitive range phototesting. While AD, its potential benefit managing more difficult measure. In 91% associated occurred 82%, albeit sometimes slight degree. However, these data suggest that, reducing eczematous response beneficial treatment worth exploring this patient cohort options are limited. Prospective studies required further evaluate utility therapeutically challenging condition.